Arizona Medicaid (AHCCCS) GLP-1 Coverage (2026): Pattern #12 — Agency-Manual Explicit Exclusion (AHCCCS FFS Provider Billing Manual Chapter 12, Item #13 + Uniform Contractor PDL Exclusions + Dual-Vendor PBM Stack + SB 1711 Deferred Dec 2025 + SB 1621 Advisory Council First Report Dec 2027)

Arizona Medicaid (AHCCCS) does NOT cover GLP-1 receptor agonists for chronic weight management. The exclusion is anchored in the AHCCCS Fee-For-Service Provider Billing Manual, Chapter 12 (Pharmacy Services), item #13 of the “AHCCCS FFS Pharmacy Exclusions” list, which states verbatim: “Medications used for weight loss treatment.” This agency-published billing manual is the most operationally direct primary-source citation in the 50-state Medicaid GLP-1 series — a single enumerated item in the agency's own standing FFS manual rather than a state administrative-code regulation, a PDL omission, or a transition bulletin. Every AHCCCS Complete Care contractor PDL verified in this analysis lists anti-obesity agents as categorically excluded. Wegovy, Zepbound, Saxenda, Foundayo, Qsymia, Contrave, and phentermine have no coverage pathway for the chronic weight-management indication. Arizona Administrative Code § R9-22-209 is silent on weight-loss drugs — unlike New York, Ohio, Illinois, and Texas, which each have explicit state-regulation anchors. AHCCCS is also unique in using a dual-vendor PBM structure: OptumRx adjudicates FFS pharmacy claims (BIN 001553, PCN AIRAZM), while Prime Therapeutics LLC serves as the separate PDL/supplemental-rebate vendor. UHC AZ Medicaid's PDL contains an internal inconsistency — Wegovy appears in both a Plan Exclusions list and a separate “Anti-Obesity Agents - Drugs for Weight Loss” tier listing — that the article addresses in detail. The 2025 Obesity Treatment Study Committee (SB 1711) voted on December 17, 2025 to defer any coverage expansion recommendation; the successor SB 1621 advisory council bill would not file its first report until December 31, 2027.

TL;DR — What AHCCCS covers (the bottom line)

• NOT covered for weight loss: Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide, any obesity/OSA dose), Saxenda (liraglutide 3 mg), Foundayo (LillyDirect tirzepatide), Qsymia, Contrave, phentermine, Adipex-P, Xenical, Lomaira, and any other FDA-approved anti-obesity medication. No MACE-only, MASH-only, or OSA-only carve-back-in pathway exists as of May 10, 2026.
• Covered for type 2 diabetes (with PA): Exenatide pens (Byetta generic, Preferred), Trulicity (dulaglutide, Preferred), Victoza (liraglutide, Preferred), Victoza authorized-generic liraglutide (Preferred), Ozempic (Tier 2 / Non-Preferred, PA + step-therapy), Mounjaro (Non-Preferred, PA + step-therapy). PA criteria: documented T2D, documented metformin trial-and-failure at ≥ 1,500 mg/day, or HbA1c ≥ 8.5% concurrent with metformin.
• FFS PBM: OptumRx, BIN 001553, PCN AIRAZM (AIR/Specialty) or PCN AZM (KidsCare). Help desk: (855) 577-6310. PDL/rebate vendor (separate): Prime Therapeutics LLC.
• Legislature: SB 1711 study committee deferred on December 17, 2025. SB 1621 advisory council bill passed Senate HHS 6-0-1 on February 18, 2026; first report due December 31, 2027 at the earliest. HB 2517 (2024) died in committee with a JLBC fiscal projection of $962.9M–$2.5B annually.

Per-state taxonomy: Pattern #12 — Agency-Manual Explicit Exclusion

In the 50-state Medicaid GLP-1 series, each state's coverage stance is anchored in a primary-source document. Arizona occupies Pattern #12: Agency-Manual Explicit Exclusion — a category unique to states whose Medicaid agency publishes the weight-loss-drug exclusion verbatim in the agency's own fee-for-service provider billing manual, rather than in a state administrative-code rule, a PDL omission, or a transition bulletin.

Compare Arizona to the prior 11 states in the series:

Arizona's distinctive structural features versus the prior eight states:

• No state administrative-code anchor. Unlike NY (18 NYCRR § 505.3(g)(3)), OH (OAC 5160-9-03(B)(1)), IL (89 IAC § 140.441(b)), and TX (1 TAC § 354.1832), Arizona's exclusion is not encoded in the Arizona Administrative Code. AAC R9-22-209 is silent on weight-loss drugs. The exclusion is administrative rather than regulatory — meaning a future AHCCCS P&T Committee decision to add Wegovy to the drug list would not require an AAC amendment first.
• No carve-back-in pathways. California restored Wegovy for MASH in January 2026. Ohio added a MACE/MASH Metabolic Modifiers class in January 2026. Pennsylvania retained MACE, MASH, and OSA carve-outs after terminating chronic-weight-management coverage. New York has a Wegovy MACE DUR pathway. Arizona has none of these; no verified AHCCCS or ACC contractor primary source establishes a non-weight-loss indication pathway for Wegovy or Zepbound as of May 10, 2026.
• Never a coverage state. Unlike Pennsylvania (which covered GLP-1s for weight loss from January 2023 through December 2025), AHCCCS has never had a coverage pathway for chronic-weight-management GLP-1s. The FFS billing manual exclusion predates the 2014 Saxenda approval and the 2021 Wegovy approval.

The AHCCCS FFS Provider Billing Manual, Chapter 12 — the canonical primary source

The AHCCCS Fee-For-Service Provider Billing Manual, Chapter 12 (Pharmacy Services), is the single most-citable primary-source statement of Arizona Medicaid's weight-loss-drug exclusion. Unlike a state administrative-code regulation (which requires rulemaking to amend), a PDL omission (which requires a reader to search for the absence of a drug), or a transition bulletin (which is dated to a specific coverage change), the billing manual is the agency's operational standing-policy document — the document that pharmacies and providers use to determine what AHCCCS will pay for at the point of service.

Verbatim from the “AHCCCS FFS Pharmacy Exclusions” section of Chapter 12 (verified by direct PDF fetch and pdftotext extraction on 2026-05-10):

“AHCCCS FFS Pharmacy Exclusions

The following are excluded from coverage under the outpatient FFS pharmacy benefit:

    1. Drug Efficacy Study Implementation (DESI) Drugs that are determined to be ‘less than fully effective’ by the Food and Drug Administration (FDA);

    2. Medications that are personally dispensed by a physician, dentist, or other provider except in geographically remote areas where there is no participating pharmacy or when accessible pharmacies are closed.

    3. Experimental/Research Drugs;

    4. Medications furnished solely for cosmetic purposes;

    5. Cosmetic Drugs for Hair Growth;

    6. Nutritional/Diet Supplements;

    7. Blood and Blood Plasma Products;

    8. Drugs and Products to Promote Fertility;

    9. Drugs used for Erectile Dysfunction Drugs unless: (a) the medication is prescribed to treat a condition other than a sexual or erectile dysfunction, and (b) the FDA has approved the medication for the specific condition.

    10. Drugs from manufacturers that do not participate in the FFS Medicaid Drug Rebate Program;

    11. Diagnostic/Medical Supplies except: (a) Syringes, (b) Needles, (c) Lancets, (d) Alcohol Swabs, (e) Blood Glucose Meters and Test Strips, (f) Inhaler devices;

    12. Intrauterine Devices;

    13. Medications used for weight loss treatment;

    14. Outpatient medications for members under the Federal Emergency Services Program, except for dialysis related medications for Extended Services individuals;

    15. Medical Marijuana (refer to AMPM Policy 320-M); and

    16. Drugs eligible for coverage under Medicare Part D for AHCCCS members eligible for Medicare whether or not the member obtains Medicare Part D coverage with the exception of Dual Eligible members that have creditable coverage and/or individuals with an SMI designation.

    17. Medications determined to be experimental as defined by the A.A.C. § 9-22-203 Experimental Services.”

Item #13 is the operative sentence. Every other element of the AHCCCS GLP-1 weight-loss story — the contractor PDL Plan Exclusions lists, the P&T preferred-drug-list omission of Wegovy and Zepbound, the Arizona Complete Health Clinical Policy AZ.CP.PMN.1004's moot status, the KJZZ reporting on the study committee — is downstream of this single clause.

The billing manual also identifies the FFS PBM. Verbatim from Chapter 12:

“AHCCCS Pharmacy Benefit Manager (PBM) Pharmacies must submit all Fee-for-Service prescription claims electronically at the point-of-sale to the AHCCCS contracted PBM, OptumRx. IHS/638 pharmacies shall submit all Fee-for-Service and KidsCare prescription claims electronically at the point-of-sale to the AHCCCS FFS PBM, OptumRx.”

And the BIN/PCN routing for FFS claims (verbatim):

“For AIR and Specialty Medication claims, the submitted ingredient cost (AAC) must be submitted using the BIN: 001553 and the PCN: AIRAZM. … Claims submitted for KidsCare must use the BIN: 001553 and the PCN: AZM.”

The federal authority permitting this exclusion is 42 U.S.C. § 1396r-8(d)(2)(A), which enumerates “Agents when used for anorexia, weight loss, or weight gain” as a class of drugs states may exclude from Medicaid pharmacy coverage without violating Medicaid Drug Rebate Program participation requirements. The billing manual's items #8 (fertility drugs), #4 and #5 (cosmetic drugs), and #9 (erectile dysfunction drugs) mirror parallel subsections of § 1396r-8(d)(2) — AHCCCS exercises essentially every available optional exclusion.

AAC § R9-22-209 — verified absence of a state regulatory anchor

Arizona Administrative Code § R9-22-209 (Pharmaceutical Services) establishes the structural framework for AHCCCS pharmaceutical-services coverage: who may prescribe, how authorization works, and what quantity limits apply. Verified by direct fetch on 2026-05-10, R9-22-209 contains zero references to obesity, weight loss, anorexia, or anti-obesity agents.

This is a structurally important finding. Four other states in the 50-state series have explicit administrative-code regulations:

• New York: 18 NYCRR § 505.3(g)(3) — “drugs for weight loss are non-covered.”
• Ohio: OAC 5160-9-03(B)(1) — “Drugs for the treatment of obesity.”
• Illinois: 89 IAC § 140.441(b) — “anorectic drugs.”
• Texas: 1 TAC § 354.1832 — drugs for weight loss are non-covered.

Arizona has none of these. The practical consequence: a future AHCCCS P&T Committee decision to add Wegovy or Zepbound to the AHCCCS Drug List would not require a prior amendment to the Arizona Administrative Code. The exclusion is administrative rather than regulatory — anchored in the agency billing manual, not in state law or regulation.

What this does not mean: AHCCCS coverage expansion is easy. The billing-manual exclusion is the agency's operational standing policy, not an informal guideline. Any change would require an affirmative AHCCCS P&T Committee vote to add AOMs to the AHCCCS Drug List and a corresponding update to Chapter 12 — or legislative direction mandating coverage. Neither is present as of May 10, 2026.

UHC AZ Medicaid PDL — the internal inconsistency every Arizona AHCCCS member should understand

The UnitedHealthcare Community Plan Arizona Medicaid PDL (effective April 1, 2026, verified by direct fetch on 2026-05-10) contains an internal inconsistency that patients and prescribers must approach carefully.

Side A — the Plan Exclusions section (verbatim, lines 195–215 of the 9,915-line extracted text):

“Plan exclusions The following drug categories are excluded from coverage under the outpatient pharmacy benefit and are not part of the UnitedHealthcare Community Plan PDL. • DESI drugs • Agents used for cosmetic hair growth • Anti-obesity agents • Drugs from manufacturers that do not participate in the FFS Medicaid Drug Rebate Program • Experimental / research drugs • Cosmetic drugs • Nutritional / diet supplements • Blood and blood plasma products • Agents used to promote fertility • Agents used for erectile dysfunction”

Side B — the Anti-Obesity Agents section (verbatim, line 3236 of the same document):

“Anti-Obesity Agents - Drugs for Weight Loss WEGOVY SUBCUTANEOUS — Tier 2; PA; QL”

This is an internal PDL contradiction. The Plan Exclusions section names “Anti-obesity agents” as categorically excluded from coverage, while a separate section of the same PDL lists Wegovy as Tier 2 with Prior Authorization and a Quantity Limit under “Anti-Obesity Agents - Drugs for Weight Loss.”

The most plausible reconciliation hypothesis — which the article states as speculative and unverified, not confirmed by UHC member services — is that Wegovy's listing reflects adjudication under its non-weight-loss FDA-approved indications: semaglutide 2.4 mg holds FDA approval for major adverse cardiovascular event (MACE) risk reduction in adults with established cardiovascular disease and overweight or obesity (SELECT trial, March 2024); and for noncirrhotic metabolic-associated steatohepatitis (MASH) with stage F2/F3 fibrosis (ESSENCE trial, March 2026). A PA-gated Wegovy listing under those non-obesity indications would not contradict the categorical exclusion of anti-obesity agents in the Plan Exclusions list, because the PA would be issued for the CV-risk-reduction or MASH indication, not for chronic weight management.

For comparison: AZ Blue Health Choice's Plan Exclusions section lists both “Anti-obesity agents” and “Weight loss drugs” as separate bulletted exclusions (verbatim from the April 1, 2026 formulary, 17,623-line extract). Molina AZ has a structural section header titled “ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS” but the section enumerates only ADHD agents — no anti-obesity drug appears in the 16,280-line Molina PDL extraction. Banner-University Family Care's April 1, 2026 formulary lists only Trulicity, Byetta, and Victoza-liraglutide for T2D; zero occurrences of Wegovy, Zepbound, or Saxenda across the 2,374-line text.

Dual-vendor PBM structure: OptumRx (FFS claims) + Prime Therapeutics (PDL/rebate)

Arizona's AHCCCS pharmacy-benefit stack is unique in the 50-state series for its dual-vendor structure: two separate vendors perform two functionally distinct pharmacy-benefit roles.

OptumRx — FFS pharmacy claims adjudication. The AHCCCS FFS Provider Billing Manual identifies OptumRx as the “AHCCCS contracted PBM” for all FFS prescription claims submitted electronically at the point of sale. Claims routing:

• AIR and Specialty Medication claims: BIN 001553, PCN AIRAZM.
• KidsCare claims: BIN 001553, PCN AZM.
• OptumRx Customer Service Help Desk: (855) 577-6310.

The FFS population covered by OptumRx includes the American Indian Health Program (AIHP) and the Department of Child Safety Comprehensive Health Plan (DCS CHP).

Prime Therapeutics LLC — PDL/supplemental-rebate vendor. Prime Therapeutics presents class reviews and preferred-drug recommendations at AHCCCS P&T Committee meetings. The October 30, 2025 AHCCCS P&T Contractor Notice identifies “Optum FFS PBM Staff” and Prime Therapeutics as separate notice recipients — confirming the distinct functional roles. Hind Douiki, PharmD, Prime Therapeutics, presented the October 22, 2025 non-supplemental-rebate class reviews per the Contractor Notice.

Critical distinction for readers: OptumRx adjudicates the resulting FFS pharmacy claims; Prime Therapeutics manages the PDL recommendations and supplemental rebates. These are contractually separate functions. A prescriber calling (855) 577-6310 (OptumRx help desk) is calling the claims-adjudication vendor, not the PDL-management vendor. For questions about which drugs are on the AHCCCS Drug List or preferred-drug status, the relevant AHCCCS contact is the AHCCCS Pharmacy Unit at azahcccs.gov/Members/Pharmacy/.

Compare Arizona's dual-vendor structure to the other states in this series:

• Texas: Acentra Health (via VDP) — single vendor for FFS PDL + PA review.
• California: Magellan (Medi-Cal Rx) — single FFS PBM.
• New York: Magellan/Prime (NYRx) — integrated.
• Ohio: Gainwell (SPBM) — single statewide PBM for all managed-care + FFS.
• Georgia FFS: OptumRx — same vendor as Arizona FFS, different state program.
• Arizona FFS: OptumRx (claims adjudication) + Prime Therapeutics (PDL/rebate) — two vendors, two roles, same AHCCCS pharmacy umbrella.

Note: several individual ACC contractors use their own PBMs for managed-care claims. AZ Blue Health Choice uses CVS/Caremark (verbatim per the April 1, 2026 formulary). Mercy Care uses CVS/Caremark (BIN 610591, PCN ADV, per secondary corroborating sources; Mercy Care's formulary page returned HTTP 403 to direct fetch on 2026-05-10 and cannot be independently verified in this analysis). Managed-care members should contact their plan's pharmacy help desk rather than OptumRx FFS.

Arizona legislation: HB 2517 (died), SB 1711 (deferred), SB 1621 (pending)

Three Arizona bills mark the four-year legislative arc on AHCCCS obesity-drug coverage. None has produced a coverage change as of May 10, 2026.

HB 2517 (2024) — mandate bill, died in committee

House Bill 2517 (Fifty-Sixth Legislature, Second Regular Session, 2024), introduced by Representative Shah, would have mandated AHCCCS to provide comprehensive obesity treatment coverage including FDA-approved anti-obesity medications. The Joint Legislative Budget Committee (JLBC) fiscal note (February 20, 2024) stated verbatim:

“Based on an analysis received from AHCCCS, we estimate the full-year cost of providing coverage of anti-obesity medication could range from $962.9 million–$2.5 billion on a Total Funds basis, including a General Fund cost range of $191.5 million–$496.2 million.”

The JLBC assumed 281,900 to 730,200 AHCCCS enrollees potentially eligible for weight-loss drugs (obesity rates of 12.8% to 33.2% of the roughly 2.1 million-enrollee base) and a per-enrollee cost of $3,795 annually — the then-current average annual cost for Trulicity T2D coverage. HB 2517 died in committee without a floor vote.

SB 1711 (2025) — study committee, voted to defer

Senate Bill 1711 (Fifty-Seventh Legislature, First Regular Session, 2025), Laws 2025 Chapter 218, signed by Governor Hobbs on June 2, 2025, established the Obesity Treatment Study Committee. Verbatim from Section 1 of the enrolled bill:

“A. The obesity treatment study committee is established to study the cost, potential savings, effectiveness, health outcomes and value of extending coverage under this state's medicaid program to include comprehensive treatment for people living with obesity.”

The committee's reporting deadline was December 31, 2025 (verbatim: “On or before December 31, 2025, the obesity treatment study committee shall submit a report regarding the study committee's activities, findings and recommendations for administrative or legislative action to the governor, the president of the senate and the speaker of the house of representatives.”). The committee repeal date is September 30, 2026.

On December 17, 2025, the bipartisan committee voted to defer rather than recommend expanded coverage. Per KJZZ's December 18, 2025 reporting, the panel “had considered recommending the Legislature expand Arizona's Medicaid program to cover the cost of GLP-1 weight loss drugs like Ozempic, but punted that decision to the new advisory committee.” Committee chair Sen. David Gowan (R-Sierra Vista). AHCCCS spokesperson Steven Berg testified at the meeting that AHCCCS currently spends about $73 million on GLP-1s annually (entirely for T2D, not weight loss), with about $13 million from the state general fund. Berg also noted that six of 14 states that had covered GLP-1s for obesity had since clawed back that coverage due to higher-than-expected utilization costs.

SB 1621 (2026) — advisory council bill, not yet enacted

Senate Bill 1621 (Fifty-Seventh Legislature, Second Regular Session, 2026), introduced by Senator Gowan, would replace the SB 1711 study committee with a longer-running Obesity Treatment and Prevention Advisory Council. The bill passed the Senate HHS Committee 6-0-1 on February 18, 2026.

The first report from the advisory council, if the bill is enacted, would not be due until December 31, 2027 (verbatim from Section 1.E: “On or before December 31, 2027 and December 31, 2028, the obesity treatment and prevention advisory council shall submit a report regarding the advisory council's activities, findings and recommendations for administrative or legislative action.”). The council repeal date would be January 30, 2029.

The article does not predict SB 1621's outcome or any downstream legislative action. The empirical record as of May 10, 2026 is: (1) the 2024 mandate bill failed; (2) the 2025 study committee deferred in December 2025; (3) the 2026 advisory council bill is in committee and would not produce its first report until December 2027 at the earliest; (4) there is no AHCCCS coverage expansion pathway from any currently enacted legislation.

AHCCCS Complete Care contractor structure — 2026-05-10 verified list

AHCCCS administers its Medicaid benefit through three managed-care delivery lines, each with distinct contractors. The following contractor list reflects the AHCCCS-published “AHCCCS Health Plans” page as verified on 2026-05-10.

Note: Care1st Health Plan Arizona and Health Net Access are NOT listed as current ACC contractors as of this verification date. Do not cite either as an active AHCCCS plan.

• AHCCCS Complete Care (ACC) — 4 contractors:
  • Banner-University Family Care (BUFC)
  • Molina Healthcare of Arizona
  • Blue Cross Blue Shield of Arizona Health Choice
  • UnitedHealthcare Community Plan
• AHCCCS Complete Care – Regional Behavioral Health Agreements (ACC-RBHA) — 2 contractors:
  • Arizona Complete Health – Complete Care Plan (Centene Corporation)
  • Mercy Care
• Arizona Long Term Care System (ALTCS) — 4 contractors: UnitedHealthcare, Banner-University Family Care, Mercy Care Plan, and DES/DDD.
• Tribal ALTCS contractors operated by the Gila River Indian Community, Hopi Tribe, Navajo Nation, Pascua Yaqui Tribe, San Carlos Apache Tribe, Tohono O'Odham Nation, White Mountain Apache Tribe, and Native American Community Health (NACH).

The fee-for-service (FFS) population — including the American Indian Health Program (AIHP) and the DCS Comprehensive Health Plan — is served by OptumRx as PBM. All managed-care populations receive their pharmacy benefit through their respective contractor. Each ACC contractor's PDL exclusions mirror the AHCCCS FFS Provider Billing Manual's item #13 exclusion under AHCCCS Policy 310-V, which requires contractor formularies to include each drug exactly as listed on the AHCCCS Drug Lists.

The type 2 diabetes distinction — what AHCCCS does and does not cover

The AHCCCS Provider Billing Manual Chapter 12 item #13 exclusion applies to the weight-management indication. GLP-1 receptor agonists prescribed and dispensed for the FDA-approved type 2 diabetes mellitus indication are a covered AHCCCS benefit.

The currently preferred T2D GLP-1 agents, per the May 21, 2025 AHCCCS P&T Committee Meeting Minutes (verbatim, effective July 1, 2025):

“Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s)

1. Bydureon Pens (Discontinued by manufacturer as supplies last)

2. Byetta Pens (Discontinued by manufacturer as supplies last)

3. Exenatide Pens (Byetta Generic) (new)

4. Trulicity

5. Victoza

6. Liraglutide (AG for Victoza) (new)”

PA criteria (verbatim from Arizona Complete Health Clinical Policy AZ.CP.PMN.183, “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists”, effective 11.16.16, last reviewed 07.2020, which mirrors the AHCCCS FFS PA criteria structure):

“I. Initial Approval Criteria

A. Type 2 Diabetes Mellitus (must meet all):

1. Diagnosis of type 2 diabetes mellitus;

2. Age is one of the following (a or b): a. Victoza: ≥ 10 years; b. All other GLP-1 receptor agonists: ≥ 18 years;

3. Member meets one of the following (a or b): a. Failure of ≥ 3 consecutive months of metformin at a minimum daily dose of 1500mg as evidenced by HbA1c ≥ 7%, unless contraindicated or clinically significant adverse effects are experienced; b. HbA1c drawn within the past 3 months is ≥ 8.5%, and concurrent use of metformin at a minimum daily dose of 1500mg, unless contraindicated or clinically significant adverse effects are experienced;

… Approval duration: 6 months”

Note on policy vintage: AZ.CP.PMN.183 was last reviewed in July 2020 and its preferred-products list references Bydureon and Byetta pens as preferred, both since discontinued by the manufacturer. The May 21, 2025 P&T Committee update (above) is more current for preferred-product status. The PA criteria structure (T2D diagnosis, metformin trial-and-failure, HbA1c thresholds) remains the operative framework pending a new policy version.

Ozempic and Mounjaro are accessible as non-preferred drugs subject to PA and step-therapy through a preferred GLP-1 agent. Neither drug triggers the weight-loss exclusion when the PA request documents the T2D indication. The distinction is the prescription indication: T2D = covered (with PA); chronic weight management = not covered.

Arizona in context: the 13-state Medicaid GLP-1 taxonomy

As of May 10, 2026, the 50-state series has published coverage analyses for Arizona plus 12 other states. Arizona's position in the broader taxonomy:

• States with explicit administrative-code anchors (AZ does not have this): New York (18 NYCRR § 505.3(g)(3)), Ohio (OAC 5160-9-03(B)(1)), Illinois (89 IAC § 140.441(b)), Texas (1 TAC § 354.1832). Arizona's exclusion is administrative, not regulatory.
• States with carve-back-in pathways for non-obesity indications (AZ does not have these): California (Wegovy MASH Jan 2026), New York (Wegovy MACE, BMI ≥ 40), Ohio (Wegovy MACE + MASH, Jan 2026 Metabolic Modifiers class), Pennsylvania (MACE/MASH/OSA retained after Jan 1, 2026 termination), New Jersey (MACE, MASH, Zepbound OSA via DURB), Washington (MACE, MASH, Zepbound OSA via WAC 182-530-2100 carve-out).
• States that reversed course and added coverage: Tennessee (positive-coverage expansion August 2025, Wegovy + Zepbound Preferred effective August 1, 2025).
• States with operational-silence exclusion (similar to Arizona but without the billing-manual explicit text): Florida (AHCA PDL absence), Georgia (Statewide PDL omission + PSHP exclusion).
• States that terminated coverage: Pennsylvania terminated chronic-weight-management coverage January 1, 2026 (34 months after first covering).

Arizona stands alone as the state whose primary anchor is the agency's own fee-for-service billing manual — not a state regulation, not a PDL absence, not a transition bulletin. The FFS billing manual enumeration makes Arizona's exclusion the most direct to cite in a PA appeal letter, a prescriber communication, or a patient explanation.

Who is affected

The following AHCCCS populations are affected by the weight-loss exclusion as of May 10, 2026:

• Adults seeking GLP-1s for chronic weight management — no coverage pathway under the AHCCCS FFS billing manual exclusion and every ACC contractor's Plan Exclusions list.
• Adults seeking older AOMs (Qsymia, Contrave, phentermine, Xenical) — excluded by the same FFS billing manual item #13. Arizona Complete Health's Clinical Policy AZ.CP.PMN.1004 lists BMI and comorbidity criteria for these agents, but the policy is operationally moot under the parent-program exclusion. AZ.CP.PMN.1004 was last reviewed in July 2020 and does not list Wegovy or Zepbound (both approved after July 2020).
• Adults seeking Wegovy for cardiovascular risk reduction (MACE) or MASH — the UHC AZ Medicaid PDL internal inconsistency (described above) may reflect a Wegovy listing for the non-obesity FDA indications only, at UHC AZ specifically. Other ACC contractors do not list Wegovy at all. Confirm with UHC Member Services before submitting a PA.
• Adults seeking Zepbound for sleep apnea (OSA) — no verified AHCCCS or ACC contractor PDL lists Zepbound for any indication. No OSA carve-back-in exists as of May 10, 2026.
• Pediatric obesity patients ages 12–17 — unlike Georgia (which lists Saxenda for ages 12–17 on the statewide PDL), AHCCCS has no verified pediatric obesity GLP-1 or AOM coverage pathway. ACH AZ.CP.PMN.1004 sets criteria for Saxenda (≥ 18 years) and phentermine (> 16 years), but the policy is moot under the parent-program exclusion.
• Arizona state employees and retirees — out of scope. The Arizona Department of Administration's State Employee Health Plan is a structurally separate program with its own formulary and PBM. This article addresses AHCCCS Medicaid only. State employees, retirees, university employees, and teachers should consult the Arizona Department of Administration directly.

Appeal pathway and patient action steps

AHCCCS members have a right to appeal any adverse coverage or prior-authorization decision. Per the AHCCCS “How to File an Appeal of a Health Care Coverage Decision” guidance (December 20, 2024 edition):

“An appeal is a request from an applicant, member, provider, health plan, or other approved entity to reconsider or change an adverse decision, also known as an action. An action includes any denial, reduction, suspension, or termination of a service or benefit, or a failure to act in a timely manner.”

Standard appeal timeline: file in writing or by phone with your health plan's Grievance and Appeals Department or call the plan's customer service line. The health plan should resolve a standard appeal within 30 days.

Expedited appeal: available when the member or prescriber believes a delay would place the member's health in serious jeopardy. Verbatim: “If the appeal is expedited, the health plan should resolve the appeal within three working days, absent an extension.”

State Fair Hearing: if the health plan's appeal decision is unfavorable, the member may request a State Fair Hearing before an administrative law judge through the Arizona Office of Administrative Hearings (OAH). AHCCCS Office of General Counsel contacts (verbatim from the guidance):

• Within Maricopa County: (602) 417-4232
• Outside Maricopa County: 1-800-654-8713, ext. 74232

Practical action steps for AHCCCS members:

1. Confirm your plan. Identify whether you are in AHCCCS Complete Care (ACC), ACC-RBHA, ALTCS, or the FFS population. Each has a different contractor and appeal contact.
2. Document the T2D indication if applicable. If you have type 2 diabetes, a GLP-1 PA for the T2D indication is a live pathway. Work with your prescriber to document HbA1c levels, metformin trial dates and doses, and any adverse effects or contraindications.
3. If you are a UHC AZ Medicaid member and have established cardiovascular disease or documented MASH, contact UHC Member Services. The UHC AZ PDL internal inconsistency on Wegovy may reflect a non-weight-loss indication PA pathway. UHC Member Services can confirm whether a Wegovy PA submission under the MACE or MASH indication would be evaluated.
4. Consider cash-pay options if the T2D PA pathway does not apply. Foundayo (LillyDirect tirzepatide, cash-pay, does not bill insurance), manufacturer patient-assistance programs, and compounding pharmacies are outside the AHCCCS coverage framework. The GLP-1 pricing index documents current cash-pay pricing at telehealth providers for members in documented-exclusion states.
5. Verify the current AHCCCS Drug List preferred-drug status. The AHCCCS P&T Committee meets quarterly. Preferred-drug status for T2D GLP-1s may change at any meeting. Current status:azahcccs.gov/Members/Pharmacy/.

Related research

• Florida Medicaid GLP-1 Coverage — Pattern #4 (Silent Exclusion) — Florida's exclusion is established by operational silence across four AHCA documents, unlike Arizona's explicit billing-manual enumeration. Both states have no MACE, MASH, or OSA carve-back-in as of May 2026.
• Texas Medicaid GLP-1 Coverage — Pattern #1 (Explicit Non-Coverage) — Texas uses the Texas Administrative Code (1 TAC § 354.1832) plus the Acentra/VDP PDL absence as its dual anchor. Arizona uses the agency billing manual rather than a state-code rule; both are non-coverage for all GLP-1 weight-loss indications with no carve-backs.
• GLP-1 Pricing Index — cash-pay pricing for AHCCCS members who do not qualify for the T2D PA pathway. Arizona is a documented-exclusion state with no MACE/MASH/OSA structural alternatives, making the cash-pay funnel the primary access route for weight-management GLP-1 prescriptions.
• GLP-1 Side Effect Questions Answered — common clinical questions about GLP-1 tolerability and dose titration, relevant for AHCCCS T2D patients navigating the preferred-to-non-preferred step-therapy pathway.